{"entity":{"id":"paper-donadel-academic-cart19-brazil-bmt-2024","kind":"paper","name":"Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil","aka":[],"tldr":"The first report of people in Brazil treated with a CAR-T cell therapy made entirely in a Brazilian public university, for leukaemia and lymphoma that had come back or stopped responding.","summary":"A two-centre retrospective report, published as a letter, from the Hospital das Clínicas de Ribeirão Preto and the Hospital das Clínicas de São Paulo (University of São Paulo). Twenty patients with relapsed or refractory B-cell non-Hodgkin lymphoma (7) or B-cell acute lymphoblastic leukaemia (13) were treated between 2019 and 2023 with an academic CD19-directed CAR-T product (HD37 clone, 4-1BB costimulatory domain). Lymphocytes were collected by apheresis, selected, activated, transduced and expanded, cryopreserved, and infused after lymphodepletion. The authors evaluated cytokine release syndrome, neurotoxicity (ICANS), cytopenias and response.","asOf":"2026-11-03","links":[{"label":"DOI: 10.1038/s41409-024-02283-6","url":"https://doi.org/10.1038/s41409-024-02283-6"}],"tags":[],"related":[],"cancers":["all-leukemia","dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["hemocentro-ribeirao-preto"],"pathways":[],"terms":[],"trials":["nct06101381"],"people":["rodrigo-calado","diego-villa-cle"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo country deep dive, Brazil (wave 2)","editedOn":"2026-11-03"},"journal":"Bone Marrow Transplantation","year":2024,"doi":"10.1038/s41409-024-02283-6","pmid":"38615142","authors":"Donadel CD, De Santis GC, Gonçalves TE, Pires BG, Palma LC, Gava F, Guerino-Cunha RL, Faria JTB, Silva GVA, Darrigo-Junior LG, Fatobene G, Rocha V, Covas DT, Calado RT, Clé DV","paperType":"observational","findings":["20 patients treated, 13 with B-cell acute lymphoblastic leukaemia and 7 with B-cell non-Hodgkin lymphoma, from 2019 to 2023.","The authors note that commercial CAR-T cell products are expensive, which has fostered alternative manufacturing such as this academic product."],"whatItMeans":"It is the evidence base for CARTHEDRALL, the multicentre trial meant to bring a national CAR-T to Brazil's public health system at a fraction of the price of imported products.","caveats":["Retrospective, small and not randomised; response and toxicity rates are in the paywalled full text and are not repeated here.","Patients were treated outside a formal trial; the prospective test is NCT06101381."],"participants":20},"route":"/key-papers/paper-donadel-academic-cart19-brazil-bmt-2024/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"hemocentro-ribeirao-preto","kind":"institution","name":"Fundação Hemocentro de Ribeirão Preto","route":"/institutions/hemocentro-ribeirao-preto/"}],"trial":[{"id":"nct06101381","kind":"trial","name":"CD19-directed CAR-T cell therapy for refractory or relapsed acute lymphoblastic leukaemia or non-Hodgkin lymphoma (CARTHEDRALL)","route":"/trials/nct06101381/"}],"person":[{"id":"diego-villa-cle","kind":"person","name":"Diego Villa Clé","route":"/people/diego-villa-cle/"},{"id":"rodrigo-calado","kind":"person","name":"Rodrigo Calado","route":"/people/rodrigo-calado/"}]}}